Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of intrathecal VO659 in Huntington's disease and spinocerebellar ataxia types 1 and 3
2026-526408-60-00Phase 2Authorised
- Sponsor
- Vico Therapeutics
- Start
- Oct 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of VO659 in Huntington disease (HD), spinocerebellar ataxia type 1 (SCA1) and machado-joseph disease (MJD) (3 arms), sponsored by Vico Therapeutics. Primary endpoints: Incidence and dose relationships of treatment-related adverse events, Changes in clinical safety parameters and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
VO659
03
Conditions
Huntington disease (HD)spinocerebellar ataxia type 1 (SCA1)machado-joseph disease (MJD)
Beyond the preview
Go deeper on 2026-526408-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526408-60-00.